Article
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Cancer discovery - 1 Jun 2018
Yoda Satoshi, Lin Jessica J, Lawrence Michael S, Burke Benjamin J, Friboulet Luc, Langenbucher Adam, Dardaei Leila, Prutisto-Chang Kylie, Dagogo-Jack Ibiayi, Timofeevski Sergei, Hubbeling Harper, Gainor Justin F, Ferris Lorin A, Riley Amanda K, Kattermann Krystina E, Timonina Daria, Heist Rebecca S, Iafrate A John, Benes Cyril H, Lennerz Jochen K, Mino-Kenudson Mari, Engelman Jeffrey A, Johnson Ted W, Hata Aaron N, Shaw Alice T
Abstract excerpt
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed previous ALK inhibitors. To define the spectrum of ALK mutations that confer lorlatinib resistance, we performed accelerated mutagenesis screening of Ba/F3 cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.